Trials / Terminated
TerminatedNCT02095821
Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange
Observational Study of Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange Therapy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- Hannover Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation. Treatment frequency is adjusted to daily measured fibrinogen blood levels to prevent bleeding complications. However, data about the correlation of fibrinogen blood levels and function of the coagulation system during plasma exchange therapy is scarce. In the present study we examine blood fibrinogen levels and coagulation factors as well as thrombin clotting time in patients under plasma exchange therapy.
Conditions
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2019-10-01
- Completion
- 2019-10-01
- First posted
- 2014-03-26
- Last updated
- 2020-04-20
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02095821. Inclusion in this directory is not an endorsement.